A three-dose study of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) in fasting conditions to determine the difference in absorption when dosed differently in healthy male participants
An open-label, randomised, three-arm crossover study to assess the absorption characteristics of different dosing strategies for ManNAc in healthy adult males
University of South Australia
20 participants
Oct 12, 2020
Interventional
Conditions
Summary
N-Acetyl-D-Mannosamine Monohydrate (ManNAc). ManNAc is a sugar (monosaccharide) which is found in humans where it plays a role in the synthesis and maintenance of muscle. In particular, it facilitates a process called ‘sialylation’. It is being studied as a supplement to treat a condition known as GNE myopathy, a rare genetic disease which is characterised by progressive skeletal muscle wasting (atrophy) caused by lack of sialylation. In other words, the disease causes the wasting and weakness of muscle which affects movement and other bodily functions resulting in disability, wheelchair use and/or incapacitation. While supplementation with ManNAc is a promising treatment for patients with GNE myopathy, we need to know more about how this sugar-like compound is absorbed after oral ingestion. We are now investigating whether we can improve the absorption of ManNAc by administering it as small amounts over a longer period of time, rather than all at once (i.e. multiple small doses of ManNAc vs one large dose of ManNAc). We are also evaluating the influence of dietary salt on the absorption of ManNAc with the aim of understanding how it is absorbed and further improving absorption.
Eligibility
Inclusion Criteria7
- The participant is a male aged 18-59 years, inclusive.
- Body mass index (BMI) is between 18-30 kg/m2 with a body weight between 45-120 kg.
- Medically healthy without any clinically significant abnormalities. Health status will be determined by the participant's medical history with specific attention to: (I) drug history identifying any known drug allergies or drug abuse, (II) any chronic use of medication, and (III) a thorough review of body systems (vital signs including an electrocardiogram (ECG), physical examination and clinical laboratory assessment).
- Adequate venous access on their left or right arm to allow for collection of multiple blood samples.
- The participant is aware of the study procedures and the risks involved, and voluntarily agrees to participate by providing written informed consent.
- The participant is willing and able to understand the study procedures and communicate effectively with study personnel.
- The participant is willing to be confined to the Clinical Trial Facility for the specified study days.
Exclusion Criteria15
- History of clinically significant central nervous system (e.g. seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions, or history of any conditions that in the opinion of the Medical Officer, may pose an unacceptable level of risk to either the participants ort study staff, may interfere with the interpretation of safety and/or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of the study compound.
- History of hypersensitivity to ManNAc or dietary salt or in the judgment of the Medical Officer, has a condition that places the participant at increased risk for adverse effects.
- Consumption of an investigational medication or a new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study treatment.
- The participant has been treated with ManNAc, sialic acid, intravenous immunoglobulin (IVIG), and/or other supplements containing sialic acid (e.g. St. John’s Wort, sialyllactose) less than 120 days prior to administration of the study compound.
- Difficulty of refraining from prescription medications and/or over the counter (OTC) products, which in the opinion of the Medical Officer might affect the results of the study or safety of the participant.
- Donation of blood or blood products in excess of 550 mL within 12 weeks prior to administration of study medication.
- History or current evidence of alcohol abuse and/or difficulty in abstaining from alcohol for 24 h prior to dose administration until the completion of blood sampling in each study period.
- History or current evidence of drug abuse, positive urine drug screen during screening, and/or difficulty in abstaining from drugs of abuse throughout the entire study.
- Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines (I.e. coffee, tea, cola, energy drinks and chocolate) for 24 h prior to dose administration until the completion of blood sampling in each study period.
- Major surgery within 4 weeks of screening.
- Uncontrolled intercurrent illness (i.e. active infection).
- Tobacco users who are unable to refrain from smoking whilst confined in the Clinical Trial Facility each study day.
- Difficulty in refraining from food and fluid (excluding water) consumption from 2200 h the night before dosing (I.e. for 10 h prior to dosing) until up to 5 h after the initial dose each treatment period.
- The participant has specific dietary requirements that prevents the consumption of a standardised meal.
- Poor compliers or those who are unlikely to attend specified study days.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is an open-label, randomised, three-arm crossover study which will be conducted in twelve healthy adult males. Consented and eligible participants will present to the Clinical Trial Facility on the morning of each study period after an overnight fast. Participants will be randomised into one of 3 treatment sequences (ABC, CBA or CAB). A 7-day washout period will occur between each treatment period. The interventions will be as follows: Treatment A: A total of 4 g ManNAc will be administered as one dose at 0 hours. Treatment B: A total of 4 g ManNAc will be administered as split 1 g doses at 0, 1, 2 and 3 hours. Treatment C: A total of 4 g ManNAc will be co-administered with 1 g table salt as one dose at 0 hours. All treatments will be orally administered as a solution.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620001127998